New leukemia treatment exceeds wildest expectations
Posted 02 August 2012 - 04:50 PM
This was a good story, but note that it is a little old (about one year). Nothing else has come up about it since.
Posted 03 August 2012 - 11:07 PM
This is being watched closely in the CLL community. Patient Power has been covering the developments since 2009, and we interviewed one of the key researchers after these stories came out in 2011 to learn more about what this work means from the patient perspective. You can find the interview here if you're interested in learning more.
Posted 04 August 2012 - 12:43 AM
MD Anderson Cancer Center is beginning research with CD19 T cells & FC also. Lets hope this going to be on a fast track.
Posted 06 August 2012 - 07:21 PM
An update: Please note the focus is on CLL, not CML.
Novartis and Penn Unite on New Anticancer Path
By KATIE THOMAS
The drugmaker Novartis and the University of Pennsylvania announced a research and licensing agreement early Monday that aims to bring to market a new approach to fighting cancer that has shown promising results in early trials.
The alliance seeks to build on the recent results of an experimental treatment that trains a person's immune system to kill cancer cells. Scientists at the university announced last year significant results in several patients with advanced chronic lymphocytic leukemia who were treated using the new technique, including two who went into complete remission.
The treatment uses a disabled form of the HIV-1 virus to carry cancer-fighting genes into the patients' T-cells, a type of white blood cell that fights viruses and tumors. Although the study involved patients with leukemia, researchers hope to apply the approach to treat patients with a variety of cancers. Other trials are under way for lymphoma, mesothelioma, myeloma and neuroblastoma.
A spokeswoman for Penn declined to comment on the financial details of the arrangement, but included in the deal is a commitment by Novartis to contribute $20 million to build the Center for Advanced Cellular Therapies, which will be devoted to studying the new treatments, on the campus.
Novartis and Penn say the deal will combine the intellectual resources of the university with the commercial wherewithal of the company, a major drugmaker. Penn is granting Novartis an exclusive worldwide license to the technologies, and Penn will receive royalty payments.
"Penn's intellectual resources, combined with a pharmaceutical industry leader like Novartis, offer a powerful symbiotic relationship in our mutual goal of finding more effective treatments for cancer," J. Larry Jameson, dean of the Perelman School of the Medicine at the University of Pennsylvania and executive vice president for the Health System, said in a statement announcing the deal.
The arrangement is being announced as major pharmaceutical companies are cutting back on their deals with biotech firms and collaborating increasingly with universities instead. Agreements between pharmaceutical companies and biotech companies totaled $18.9 billion in the first seven months of this year, a decline from the $22.7 billion in deals that were done over the same period a year ago, according to a recent report by the venture capital firm Burrill & Company.
The downside, said G. Steven Burrill, chief executive of Burrill, is that Novartis and other companies will be taking on more risk by getting involved in research at its earliest phases. "Now they're going to own all of the development, both the risk and the cost," he said.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users